Literature DB >> 7517557

The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

I Warshawsky1, G J Broze, A L Schwartz.   

Abstract

The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) is a cell-surface glycoprotein of 4525 amino acids that functions as a hepatic endocytosis receptor for several plasma proteins. These include alpha 2-macroglobulin-protease complexes, free plasminogen activators as well as plasminogen activators complexed with their inhibitors, and beta-migrating very low density lipoproteins complexed with either apolipoprotein E or lipoprotein lipase. In the current study we used human and rat hepatoma cell lines to demonstrate that LRP can mediate the degradation of tissue factor pathway inhibitor (TFPI), a Kunitz-type plasma serine protease inhibitor that regulates tissue factor-induced blood coagulation. The cellular degradation of 125I-labeled TFPI (125I-TFPI) was inhibited more than 80% both by antibodies directed against LRP and by the LRP-associated 39-kDa protein, a protein that inhibits the binding and/or cell-mediated degradation of all ligands by LRP. Using rat hepatoma cells, we report that at 4 degrees C, 125I-TFPI binds to approximately 2 x 10(6) sites per cell with an equilibrium dissociation constant of approximately 30 nM. 125I-TFPI binding to the cell surface is not inhibited by the 39-kDa protein. Taken together, our results suggest that TFPI binds to an as-yet-unidentified cell surface molecule. After binding, LRP mediates the cellular degradation of TFPI.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517557      PMCID: PMC44263          DOI: 10.1073/pnas.91.14.6664

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  The role of tissue factor pathway inhibitor in a revised coagulation cascade.

Authors:  G J Broze
Journal:  Semin Hematol       Date:  1992-07       Impact factor: 3.851

2.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

Authors:  M P Stoppelli; A Corti; A Soffientini; G Cassani; F Blasi; R K Assoian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

3.  Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.

Authors:  D Collen; F De Cock; H R Lijnen
Journal:  Thromb Haemost       Date:  1984-08-31       Impact factor: 5.249

Review 4.  Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.

Authors:  M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

5.  Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins.

Authors:  A R Hubbard; C A Jennings
Journal:  Thromb Res       Date:  1987-05-15       Impact factor: 3.944

6.  Association of plasma lipoproteins with postheparin lipase activities.

Authors:  I J Goldberg; J J Kandel; C B Blum; H N Ginsberg
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

7.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

Authors:  P M Sandset; U Abildgaard; M L Larsen
Journal:  Thromb Res       Date:  1988-06-15       Impact factor: 3.944

8.  Hepatic and extrahepatic uptake of intravenously injected lipoprotein lipase.

Authors:  L Wallinder; J Peterson; T Olivecrona; G Bengtsson-Olivecrona
Journal:  Biochim Biophys Acta       Date:  1984-10-04

9.  Characterization of the asialoglycoprotein receptor in a continuous hepatoma line.

Authors:  A L Schwartz; S E Fridovich; B B Knowles; H F Lodish
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

10.  Hepatic clearance of tissue-type plasminogen activator in rats.

Authors:  J J Emeis; C M van den Hoogen; D Jense
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

View more
  22 in total

1.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

Review 2.  LDL receptor-related protein-1: a regulator of inflammation in atherosclerosis, cancer, and injury to the nervous system.

Authors:  Steven L Gonias; W Marie Campana
Journal:  Am J Pathol       Date:  2013-10-12       Impact factor: 4.307

3.  Effect of dietary cholesterol on low density lipoprotein-receptor, 3-hydroxy-3-methylglutaryl-CoA reductase, and low density lipoprotein receptor-related protein mRNA expression in healthy humans.

Authors:  P Boucher; M de Lorgeril; P Salen; P Crozier; J Delaye; J J Vallon; A Geyssant; R Dante
Journal:  Lipids       Date:  1998-12       Impact factor: 1.880

Review 4.  Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity.

Authors:  Dudley K Strickland; Dianaly T Au; Patricia Cunfer; Selen C Muratoglu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-06       Impact factor: 8.311

Review 5.  Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation.

Authors:  Eric W Holroyd; Robert D Simari
Journal:  Thromb Res       Date:  2010-02-24       Impact factor: 3.944

6.  Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor.

Authors:  A E Mast; D A Higuchi; Z F Huang; I Warshawsky; A L Schwartz; G J Broze
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

7.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.

Authors:  S K Moestrup; S Cui; H Vorum; C Bregengård; S E Bjørn; K Norris; J Gliemann; E I Christensen
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

Authors:  I Warshawsky; G Bu; A Mast; J E Saffitz; G J Broze; A L Schwartz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

Authors:  Shuchong Pan; Thomas A White; Tyra A Witt; Anca Chiriac; Cheri S Mueske; Robert D Simari
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

10.  The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro.

Authors:  T E Willnow; J M Moehring; N M Inocencio; T J Moehring; J Herz
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.